Molecular profiling (such as gene mutations, aberrant signaling pathways), including genomics, transcriptomics, and proteomics, holds significant promise for refining patient selection and optimizing treatment efficacy in PSMA-targeted therapies for PCa (98). Here, FOLH1 is linked to posterior cortical atrophy.